Irvine Scientific launches new xeno-free medium for hematopoietic progenitor cell culture
![](/46/pdcnewsitem/04/64/10/clip_image003%20(1).jpg)
New medium designed for hematopoietic cell culture for cell-based therapies.
Irvine Scientific has added to its expanding line of products to support stem and immunological cell therapies with the introduction of PRIME-XV Hematopoietic Cell Basal Medium. This new formulation follows other media in the PRIME-XV line as it is another serum-free, xeno-free basal medium that specifically supports robust expansion of hematopoietic progenitors while maintaining their multipotency, or functional properties needed for cell-based therapies.
Hematopoietic stem and progenitor cells (HSPCs) give rise to all other blood cells, and therefore have therapeutic potential for the treatment of cancers such as leukemia and lymphoma, and non-malignant diseases such as sickle cell anemia or immune related disorders. To be effective, however, there must be sufficient numbers of HSPCs that retain their progenitor cell properties, including self-renewal and multipotency, to provide successful therapies.
HSPCs are often obtained from the blood or bone marrow of donors and are rare (only 1 in 100,000 in peripheral blood cells and 1 in 10,000 in bone marrow). With numbers of cells in the 100’s of millions required for therapy the challenge has been obtaining sufficient numbers of HSPCs that maintain their progenitor cell properties to differentiate and mature into the various hematopoietic lineage cells needed for therapies.
“In ex vivo culture HSPCs tend to spontaneously differentiate over time making it difficult to obtain large numbers of multipotent cells,” explained Dr Jessie Ni, Chief Scientific Officer, Irvine Scientific. “When supplemented with the appropriate cytokines, PRIME-XV Hematopoietic Cell Basal Medium is formulated to support robust expansion of cell numbers while maintaining high percentages of multipotent hematopoietic progenitor cells.”
Its serum-free, xeno-free formula reduces the risks of contamination associated with media containing serum or non-human, animal-derived components. PRIME-XV Hematopoietic Cell Basal Medium is manufactured using stringent raw material qualification and under cGMP for consistency, reliability and to make the move from research towards clinical applications.
Related News
-
News Eli Lilly’s Alzheimer’s drug receives approval from US FDA
After facing several hurdles on its path to approval last year, Eli Lilly’s donanemab treatment for early Alzheimer’s, brand name Kisunla, received US FDA approval this past week. It is the second therapy for slowing the progression of Alzh... -
News This week in GLP-1 drug headlines: Manufacturing investment and new market launches
As drugmakers race to put their own GLP-1 drug products forward as the next biggest thing in weight-loss, current products are making numerous headlines this week with a number of new developments in their commercialisation and approval. Discover the l... -
News Women in Pharma: Regulating equity across regional borders
In our monthly series focusing on women in the pharmaceutical industry, we interview leading experts in the pharmaceutical supply and value chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News Viral marketing for B2B pharma businesses: a CPHI Online case study
Discover how a Chinese chemical manufacturing company went viral on TikTok, and what their viral success means for the future of B2B digital marketing for the wider pharmaceutical industry and supply chain. -
News New Aurigene biologics facility opens in Hyderabad, India
Aurigene Pharmaceutical Services Ltd. have opened a biologics facility in Hyderabad, India in a biocluster known as Genome Valley. -
News Novo Nordisk launches 'Power of Wegovy' national campaign
Danish drugmaker Novo Nordisk have launched a new national campaign – The Power of Wegovy – that aims to educate those living with obesity on their blockbuster drug Wegovy throughout the United States. -
News Women in Pharma Anniversary: Celebrating Our Heroines of Pharma
Our Women in Pharma interview series is approaching its 1-year anniversary this month, and to celebrate, we are highlighting the Heroines of Pharma that our very own Women in Pharma admire. -
News Sanofi gains rare disease therapy in acquisition of Inhibrx for US$1.7 billion
Sanofi completed the acquisition of the clinical-stage biotech company Inhibrx in late May 2024 after settling on a US$1.7 billion buyout. The acquisition brings with it a rare disease therapy to bollster Sanofi's pipeline.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance